Bio-Techne (TECH) Non-Current Debt (2014 - 2026)
Bio-Techne (TECH) posted quarterly Non-Current Debt of $200.0 million for Q1 2026, down 39.39% year-over-year from $330.0 million in Q1 2025, and down 23.08% quarter-over-quarter from $260.0 million in Q4 2025.
Bio-Techne (TECH) Non-Current Debt (2014 - 2026) Analysis & Trends
Bio-Techne's Non-Current Debt history runs 13 years deep, the most recent figure standing at $200.0 million for Q1 2026.
- In Q1 2026, Non-Current Debt fell 39.39% year-over-year to $200.0 million; the TTM figure through Mar 2026 stood at $200.0 million (down 39.39% YoY), while the FY2025 annual figure was $346.0 million, up 8.46% from the prior year.
- Non-Current Debt for Q1 2026 stood at $200.0 million, down from $260.0 million in the prior quarter.
- The five-year high for Non-Current Debt was $447.0 million in Q4 2023, with the low at $200.0 million in Q4 2022.
- The 5-year median for Non-Current Debt is $300.0 million (2024), against an average of $312.1 million.
- The sharpest annual moves came in 2023 and 2026: Non-Current Debt jumped 123.5% in 2023, then plunged 39.39% in 2026.
- Bio-Techne's Non-Current Debt stood at $200.0 million in 2022, then jumped by 123.5% to $447.0 million in 2023, then slumped by 32.89% to $300.0 million in 2024, then declined by 13.33% to $260.0 million in 2025, then retreated by 23.08% to $200.0 million in 2026.
- Business Quant data shows TECH's Non-Current Debt at $200.0 million in Q1 2026, $260.0 million in Q4 2025, and $300.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Bio-Techne | 11.33 Bn | 11.12 Bn | 208.29 Mn | 200.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 200.00 Mn |
| Dec 31, 2025 | 260.00 Mn |
| Sep 30, 2025 | 300.00 Mn |
| Jun 30, 2025 | 346.00 Mn |
| Mar 31, 2025 | 330.00 Mn |
| Dec 31, 2024 | 300.00 Mn |
| Sep 30, 2024 | 300.00 Mn |
| Jun 30, 2024 | 319.00 Mn |
| Mar 31, 2024 | 389.00 Mn |
| Dec 31, 2023 | 447.00 Mn |
| Sep 30, 2023 | 440.00 Mn |
| Jun 30, 2023 | 350.00 Mn |
| Mar 31, 2023 | 370.00 Mn |
| Dec 31, 2022 | 200.00 Mn |
| Sep 30, 2022 | 264.66 Mn |
| Jun 30, 2022 | 243.41 Mn |
| Mar 31, 2022 | 246.51 Mn |
| Dec 31, 2021 | 269.62 Mn |
| Sep 30, 2021 | 287.72 Mn |
| Jun 30, 2021 | 328.83 Mn |